Asymmetric Dimethyl Arginine as a Biomarker of Atherosclerosis in Rheumatoid Arthritis
Cardiovascular disease is the main cause of morbidity and mortality in rheumatoid arthritis (RA). Despite the advent on new drugs targeting the articular manifestations, the burden of cardiovascular disease is still an unmet need in the management of RA. The pathophysiology of accelerated atheroscle...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2018/3897295 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832545640148631552 |
|---|---|
| author | Manuela Di Franco Bruno Lucchino Fabrizio Conti Guido Valesini Francesca Romana Spinelli |
| author_facet | Manuela Di Franco Bruno Lucchino Fabrizio Conti Guido Valesini Francesca Romana Spinelli |
| author_sort | Manuela Di Franco |
| collection | DOAJ |
| description | Cardiovascular disease is the main cause of morbidity and mortality in rheumatoid arthritis (RA). Despite the advent on new drugs targeting the articular manifestations, the burden of cardiovascular disease is still an unmet need in the management of RA. The pathophysiology of accelerated atherosclerosis associated to RA is not yet fully understood, and reliable and specific markers of early cardiovascular involvement are still lacking. Asymmetric dimethylarginine is gaining attention for its implication in the pathogenesis of endothelial dysfunction and as biomarkers of subclinical atherosclerosis. Moreover, the metabolic pathway of methylarginines offers possible targets for therapeutic interventions to decrease the cardiovascular risk. The purpose of this review is to describe the main causes of increased methylarginine levels in RA, their implication in accelerated atherosclerosis, the possible role as biomarkers of cardiovascular risk, and finally the available data on current pharmacological treatment. |
| format | Article |
| id | doaj-art-410590c45e9943d1a3a22db359760d55 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-410590c45e9943d1a3a22db359760d552025-02-03T07:25:07ZengWileyMediators of Inflammation0962-93511466-18612018-01-01201810.1155/2018/38972953897295Asymmetric Dimethyl Arginine as a Biomarker of Atherosclerosis in Rheumatoid ArthritisManuela Di Franco0Bruno Lucchino1Fabrizio Conti2Guido Valesini3Francesca Romana Spinelli4Dipartimento di Medicina Interna e Specialità Mediche-Reumatologia, Sapienza Università di Roma, Rome, ItalyDipartimento di Medicina Interna e Specialità Mediche-Reumatologia, Sapienza Università di Roma, Rome, ItalyDipartimento di Medicina Interna e Specialità Mediche-Reumatologia, Sapienza Università di Roma, Rome, ItalyDipartimento di Medicina Interna e Specialità Mediche-Reumatologia, Sapienza Università di Roma, Rome, ItalyDipartimento di Medicina Interna e Specialità Mediche-Reumatologia, Sapienza Università di Roma, Rome, ItalyCardiovascular disease is the main cause of morbidity and mortality in rheumatoid arthritis (RA). Despite the advent on new drugs targeting the articular manifestations, the burden of cardiovascular disease is still an unmet need in the management of RA. The pathophysiology of accelerated atherosclerosis associated to RA is not yet fully understood, and reliable and specific markers of early cardiovascular involvement are still lacking. Asymmetric dimethylarginine is gaining attention for its implication in the pathogenesis of endothelial dysfunction and as biomarkers of subclinical atherosclerosis. Moreover, the metabolic pathway of methylarginines offers possible targets for therapeutic interventions to decrease the cardiovascular risk. The purpose of this review is to describe the main causes of increased methylarginine levels in RA, their implication in accelerated atherosclerosis, the possible role as biomarkers of cardiovascular risk, and finally the available data on current pharmacological treatment.http://dx.doi.org/10.1155/2018/3897295 |
| spellingShingle | Manuela Di Franco Bruno Lucchino Fabrizio Conti Guido Valesini Francesca Romana Spinelli Asymmetric Dimethyl Arginine as a Biomarker of Atherosclerosis in Rheumatoid Arthritis Mediators of Inflammation |
| title | Asymmetric Dimethyl Arginine as a Biomarker of Atherosclerosis in Rheumatoid Arthritis |
| title_full | Asymmetric Dimethyl Arginine as a Biomarker of Atherosclerosis in Rheumatoid Arthritis |
| title_fullStr | Asymmetric Dimethyl Arginine as a Biomarker of Atherosclerosis in Rheumatoid Arthritis |
| title_full_unstemmed | Asymmetric Dimethyl Arginine as a Biomarker of Atherosclerosis in Rheumatoid Arthritis |
| title_short | Asymmetric Dimethyl Arginine as a Biomarker of Atherosclerosis in Rheumatoid Arthritis |
| title_sort | asymmetric dimethyl arginine as a biomarker of atherosclerosis in rheumatoid arthritis |
| url | http://dx.doi.org/10.1155/2018/3897295 |
| work_keys_str_mv | AT manueladifranco asymmetricdimethylarginineasabiomarkerofatherosclerosisinrheumatoidarthritis AT brunolucchino asymmetricdimethylarginineasabiomarkerofatherosclerosisinrheumatoidarthritis AT fabrizioconti asymmetricdimethylarginineasabiomarkerofatherosclerosisinrheumatoidarthritis AT guidovalesini asymmetricdimethylarginineasabiomarkerofatherosclerosisinrheumatoidarthritis AT francescaromanaspinelli asymmetricdimethylarginineasabiomarkerofatherosclerosisinrheumatoidarthritis |